This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Santoni-Rugiu, E. Articles by Thorgeirsson, S. S. Search for Related Content PubMed PubMed Citation Articles by Santoni-Rugiu, E. Articles by Thorgeirsson, S. S.

(American Journal of Pathology. 1999;154:1693-1700.)
© 1999 American Society for Investigative Pathology

Regular Articles

Acceleration of c-myc-Induced Hepatocarcinogenesis by Co-Expression of Transforming Growth Factor (TGF)- in Transgenic Mice Is Associated with TGF-ß1 Signaling Disruption

Eric Santoni-Rugiu^*, Michael R. Jensen^*, Valentina M. Factor^* and Snorri S. Thorgeirsson^*

From the Laboratory of Experimental Carcinogenesis,^*
Division of Basic Sciences, National Cancer Institute, Bethesda, Maryland, and the Department of Experimental Pathology,
University of Pisa, Pisa, Italy

We have previously shown in transgenic mice that transforming growth factor (TGF)- dramatically enhances c-myc-induced hepatocarcinogenesis by promoting proliferation and survival of hepatocellular carcinoma (HCC) cells. As transgenic livers display increased levels of mature TGF-ß1 from the early stages of hepatocarcinogenesis, we have now assessed whether impairment of TGF-ß1 signaling contributes to the deregulation of cell cycle progression and apoptosis observed during this process. Focal preneoplastic lesions lacking expression of TGF-ß receptor type II (TßRII) were detected in c-myc/TGF- but not in c-myc livers. In c-myc/TGF- mice, 40% (2/5) of adenomas and 90% (27/30) of HCCs showed down-regulation of TßRII expression in comparison with 11% (2/18) of adenomas and 47% (14/30) of HCCs in c-myc mice. Down-regulation of the TGF-ß1-inducible p15^INK4B mRNA and reduced apoptotic rates in TßRII-negative HCCs further indicated the disruption of TGF-ß1 signaling. Furthermore, both TßRII-negative and -positive c-myc TGF- HCCs, but not c-myc HCCs, were characterized by decreased levels of the cell cycle inhibitor p27. These results suggest 1) an inverse correlation of decreased p27 expression with the particularly strong expression of TGF- in these lesions, consistent with the capacity of TGF- signaling to post-transcriptionally regulate p27, and 2) the presence of alternative, downstream defects of TGF-ß1 signaling in c-myc/TGF- HCCs that may impair the growth-inhibitory response to TGF-ß1. Thus, the accelerated neoplastic development in c-myc/TGF- mice is associated with an early and frequent occurrence of TßRII-negative lesions and with reduced levels of p27 in HCC cells, indicating that disruption of TGF-ß1 responsiveness may play a crucial role in the enhancement of c-myc-induced hepatocarcinogenesis by TGF-.

This article has been cited by other articles:

				E. Mendieta-Condado, M. Pichardo-Olvera, L. Sanchez-Sevilla, V. Chagoya de Sanchez, and R. Hernandez-Munoz Adenosine Administration Accelerates Progression of the Cell Cycle during Rat Liver Regeneration Induced by One-Third Hepatectomy J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 122 - 132. [Abstract] [Full Text] [PDF]

				D. F. Calvisi and S. S. Thorgeirsson Molecular Mechanisms of Hepatocarcinogenesis in Transgenic Mouse Models of Liver Cancer Toxicol Pathol, January 1, 2005; 33(1): 181 - 184. [Abstract] [Full Text] [PDF]

				A. B. Rogers, S. R. Boutin, M. T. Whary, N. Sundina, Zhongming Ge, K. Cormier, and J. G. Fox Progression of Chronic Hepatitis and Preneoplasia in Helicobacter hepaticus-Infected A/JCr Mice Toxicol Pathol, October 1, 2004; 32(6): 668 - 677. [Abstract] [PDF]

				M. Nakau, H. Miyoshi, M. F. Seldin, M. Imamura, M. Oshima, and M. M. Taketo Hepatocellular Carcinoma Caused by Loss of Heterozygosity in Lkb1 Gene Knockout Mice Cancer Res., August 15, 2002; 62(16): 4549 - 4553. [Abstract] [Full Text] [PDF]

				Do Youn Park, Soon Yeol Hwang, and Kang Suek Suh Expression of Transforming Growth Factor (TGF)-{beta}1 and TGF-{beta} Type II Receptor in Preneoplastic Lesions During Chemical Hepatocarcinogenesis of Rats Toxicol Pathol, August 1, 2001; 29(5): 541 - 549. [Abstract] [PDF]

				S. Yang, H. Z. Lin, J. Hwang, V. P. Chacko, and A. M. Diehl Hepatic Hyperplasia in Noncirrhotic Fatty Livers: Is Obesity-related Hepatic Steatosis a Premalignant Condition? Cancer Res., July 1, 2001; 61(13): 5016 - 5023. [Abstract] [Full Text] [PDF]

				D. F. Calvisi, V. M. Factor, R. Loi, and S. S. Thorgeirsson Activation of {beta}-Catenin during Hepatocarcinogenesis in Transgenic Mouse Models: Relationship to Phenotype and Tumor Grade Cancer Res., March 1, 2001; 61(5): 2085 - 2091. [Abstract] [Full Text]

				E. Santoni-Rugiu, J. Falck, N. Mailand, J. Bartek, and J. Lukas Involvement of Myc Activity in a G1/S-Promoting Mechanism Parallel to the pRb/E2F Pathway Mol. Cell. Biol., May 15, 2000; 20(10): 3497 - 3509. [Abstract] [Full Text] [PDF]

				V. M. Factor, D. Laskowska, M. R. Jensen, J. T. Woitach, N. C. Popescu, and S. S. Thorgeirsson Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model PNAS, February 29, 2000; 97(5): 2196 - 2201. [Abstract] [Full Text] [PDF]